New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2731-7196
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
New treatment options for metastatic HER2-low breast cancer ; day:6 ; month:12 ; year:2022 ; pages:1-8
Die Pathologie ; (6.12.2022), 1-8
- Creator
-
Denkert, Carsten
Lebeau, Annette
Schildhaus, Hans Ulrich
Jackisch, Christian
Rüschoff, Josef
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00292-022-01139-4
- URN
-
urn:nbn:de:101:1-2023021621125355675294
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Denkert, Carsten
- Lebeau, Annette
- Schildhaus, Hans Ulrich
- Jackisch, Christian
- Rüschoff, Josef
- SpringerLink (Online service)
Other Objects (12)
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
Targeted therapies for ER+/HER2- metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Histopathological features predict metastatic potential in locally advanced colon carcinomas
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Histopathological Criteria for Paediatric Adrenocortical Carcinoma
Treatment Options in Metastatic Renal Cell Carcinoma
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
Targeted therapies for ER+/HER2- metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Histopathological features predict metastatic potential in locally advanced colon carcinomas
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Histopathological Criteria for Paediatric Adrenocortical Carcinoma
Treatment Options in Metastatic Renal Cell Carcinoma
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Treatment Options for Patients with Brain Metastatic Disease in HER2-Positive Breast Cancer
Targeted therapies for ER+/HER2- metastatic breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Histopathological features predict metastatic potential in locally advanced colon carcinomas
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
Histopathological Criteria for Paediatric Adrenocortical Carcinoma
Treatment Options in Metastatic Renal Cell Carcinoma
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy